Epixis' hep C vaccine shows early promise

French biotech company Epixis says it's used its experimental hepatitis C vaccine to fight off a variety of hepatitis C viruses in animal trials by spawning neutralizing antibodies. The developer is being purchased by an undisclosed U.S. company. Report

Suggested Articles

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.

Cosette Pharmaceuticals which was formed in December with a deal for dermatology projects has gone back to G&W Labs for a liquids plant.

Takeda has spent considerable resources on its phase 3 dengue vaccine, and now data show the shot was 80% effective in preventing dengue.